RxDoctor Payments Data

Berne Bahnson, MD

Psychiatry · Sioux Falls, SDNPI 1871565499

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations.

$949in general payments, 2019–2025

Across 77 payments — averaging $12.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shire North American Group Inc$227
  • Otsuka America Pharmaceutical, Inc.$172
  • Takeda Pharmaceuticals U.S.A., Inc.$142
  • Acadia Pharmaceuticals Inc$61
  • Lundbeck LLC$58
  • Neos Therapeutics, LP$56
  • plus $234 from 9 others

What the payments were for

  • Food & beverage$949100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$949 in reported general payments places this provider in the 70th percentile of 79 psychiatry providers in South Dakota.

See all psychiatry providers in South Dakota

Medicare billing

Part B allowed, 2024
$47,278
Medicare patients
176
Services billed
438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate23$173,625
Invega SustennaPaliperidone Palmitate33$79,831
AristadaAripiprazole Lauroxil26$76,525
RexultiBrexpiprazole34$52,160
VraylarCariprazine Hcl26$39,490
VyvanseLisdexamfetamine Dimesylate97$35,889
FanaptIloperidone12$21,117
Lurasidone Hcl60$18,297
BelsomraSuvorexant43$17,942
Lisdexamfetamine Dimesylate45$10,058
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine117$6,919
FetzimaLevomilnacipran Hcl12$5,775
Clozapine76$5,668
Olanzapine134$5,453
Bupropion XlBupropion Hcl313$4,856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$13$173,62523 claims
Johnson & JohnsonInvega Sustenna$35$79,83133 claims
Otsuka America Pharmaceutical, Inc.Rexulti$172$52,16034 claims
AbbVieVraylar, Fetzima$12$45,26538 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$142$35,88997 claims
MerckBelsomra$39$17,94243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 79 psychiatry providers in South Dakota.

Other psychiatry in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →